## MRK: Merck & Company, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.80 indicates fundamental undervaluation. Quality metrics strong (ROE 40%, ROA 14%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-2.4% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($93.83)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. EDENTREE ASSET MANAGEMENT Ltd Purchases 15,000 Shares of Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20251211T094831 | Bullish | Relevance: 99%
-  EDENTREE ASSET MANAGEMENT Ltd increased its stake in Merck & Co., Inc. (NYSE:MRK) by 14.2%, acquiring an additional 15,000 shares to hold a total of 120,865 shares valued at $9.56 million. Merck recently surpassed EPS estimates, reported strong revenue, and raised its quarterly dividend to $0.85 per share. Institutional investors collectively own about 76.07% of Merck's stock, indicating significant interest.

**2. Investment House LLC Sells 75,437 Shares of Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20251211T131932 | Somewhat-Bullish | Relevance: 99%
-  Investment House LLC significantly reduced its stake in Merck & Co., Inc. by selling 75,437 shares, valuing its remaining holdings at $4.804 million. Despite this, other institutional investors increased their positions, and Merck reported strong quarterly earnings, beating expectations and raising its dividend. Analysts currently have a "Hold" consensus rating for Merck with a target price of $107.38.

**3. Merck & Co., (MRK) Gets Conditional Approval For EXZOLT CATTLE-CA1**
- Source: Insider Monkey | 20251211T073300 | Bullish | Relevance: 99%
-  Merck & Co., Inc. (NYSE: MRK) has received conditional approval from the FDA for EXZOLT CATTLE-CA1, a topical solution to treat New World screwworm larvae infestations. This accelerated approval is for a serious zoonotic disease, making the drug available by prescription in early 2025, though it still requires a full demonstration of effectiveness. Guggenheim also raised its price target for Merck to $122, factoring in potential revenues from Winrevair.

**4. Merck & Co., Inc. (NYSE:MRK) Stock Price Down 2% - Here's What Happened**
- Source: MarketBeat | 20251209T224024 | Neutral | Relevance: 99%
-  Merck & Co., Inc. (NYSE:MRK) shares dropped 2% during mid-day trading on Tuesday, with approximately 15.26 million shares traded. The company recently reported strong Q3 earnings, beating analyst expectations, and increased its quarterly dividend. Analyst ratings are mixed, with several firms raising price targets while others maintain a "Hold" or "Sell" rating.

**5. Investment Management Corp of Ontario Boosts Stock Holdings in Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20251209T141523 | Somewhat-Bullish | Relevance: 98%
-  Investment Management Corp of Ontario significantly increased its stake in Merck & Co., Inc. by 79.5% in the second quarter, now owning 224,147 shares valued at $17.74 million. Other hedge funds also adjusted their positions, and insider selling by EVP David Michael Williams was reported. Analysts have issued varied ratings, with a consensus "Hold" and an average price target of $107.38.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Scotiabank | $120 | $105 | +14% |
| 2025-12-02 | Goldman Sachs | $120 | $92 | +30% |
| 2025-11-24 | Wells Fargo | $125 | $90 | +39% |
| 2025-11-18 | Deutsche Bank | $111 | $110 | +1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Scotiabank | main | Sector Outperform |
| 2025-12-02 | Goldman Sachs | main | Buy |
| 2025-11-24 | Wells Fargo | up | Overweight |
| 2025-11-18 | Deutsche Bank | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.09M) |
| Sells | 2 ($1.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.2% (-0.3%)
- Blackrock Inc.: 8.7% (-1.6%)
- State Street Corpora: 4.8% (-0.3%)
- Wellington Managemen: 3.0% (-2.0%)
- JPMORGAN CHASE & CO: 2.8% (+121.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.4% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +21%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.80 indicates undervaluation relative to growth. Quality metrics strong (ROE 40%, ROA 14%, margin 30%). Balance sheet: $6.8B free cash flow. Analyst sentiment positive (4 raises, avg +21%). Insider selling cluster ($1.3M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $247.3B |
| Beta | 0.30 |
| 52W Range | $73.31 - $105.84 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.80 |
| Forward P/E | 11.5 |
| Current P/E | 11.0 |
| YoY Growth | -4.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.5% to -1.9% (-2.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.9pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.6%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.79), momentum weakening. RSI neutral at 57.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.94% (CS: 31) | Neutral |
| RSI_14 | 57.1 | Neutral |
| MACD Histogram | -0.79 | Bearish |
| vs SMA20 | 1.002x | Above |
| vs SMA50 | 1.082x | Above |
| vs SMA200 | 1.165x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $99.01
- **Stop Loss:** $93.83 (5.2% risk)
- **Target:** $109.37 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 266
- **Position Value:** $26,336.66
- **Portfolio %:** 26.34%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-03 (Est: $2.05)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.58 | +9.9% |
| 2025Q2 | $2.03 | $2.13 | +5.0% |
| 2025Q1 | $2.14 | $2.22 | +4.0% |
| 2024Q4 | $1.67 | $1.72 | +3.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*